Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas.

Akerstrom V, Chen C, Lan MS, Breslin MB.

Cancer Gene Ther. 2012 Dec;19(12):828-38. doi: 10.1038/cgt.2012.66. Epub 2012 Oct 19.

PMID:
23079673
2.

INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.

Wang HW, Breslin MB, Chen C, Akerstrom V, Zhong Q, Lan MS.

Hum Gene Ther. 2009 Nov;20(11):1308-18. doi: 10.1089/hum.2008.168.

4.

Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase.

Tseng AW, Akerstrom V, Chen C, Breslin MB, Lan MS.

Int J Oncol. 2016 Jan;48(1):173-80. doi: 10.3892/ijo.2015.3223. Epub 2015 Oct 30.

PMID:
26530405
5.

Tumor-specific promoter-driven adenoviral therapy for insulinoma.

Tseng AW, Chen C, Breslin MB, Lan MS.

Cell Oncol (Dordr). 2016 Jun;39(3):279-86. doi: 10.1007/s13402-016-0274-8. Epub 2016 Feb 22.

PMID:
26902080
6.

The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer.

Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS.

Cancer Gene Ther. 2006 Apr;13(4):375-84.

PMID:
16052225
7.

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS.

J Gene Med. 2012 Jul;14(7):445-58. doi: 10.1002/jgm.2630.

PMID:
22576955
8.

Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer.

Su GQ, Su G, Huang ZH.

Mol Med Rep. 2012 Aug;6(2):321-9. doi: 10.3892/mmr.2012.925. Epub 2012 May 23.

PMID:
22641384
9.

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.

Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.

Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43. Epub 2011 Aug 12.

PMID:
21836632
10.

Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.

Wang ZX, Bian HB, Yang JS, De W, Ji XH.

Cancer Biol Ther. 2009 Aug;8(15):1480-8. Epub 2009 Aug 8.

PMID:
19571664
11.

Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression.

Millecamps S, Kiefer H, Navarro V, Geoffroy MC, Robert JJ, Finiels F, Mallet J, Barkats M.

Nat Biotechnol. 1999 Sep;17(9):865-9.

PMID:
10471926
12.
13.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

14.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

15.

Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.

Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV.

J Gastrointest Surg. 2009 Jun;13(6):1044-51. doi: 10.1007/s11605-009-0839-1. Epub 2009 Mar 10.

PMID:
19277794
16.

Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.

Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT.

Cancer Res. 2000 Aug 15;60(16):4305-10.

17.

Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.

Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA.

Urology. 2004 Mar;63(3):613-8.

PMID:
15028478
18.

The neuron-restrictive silencer element: a dual enhancer/silencer crucial for patterned expression of a nicotinic receptor gene in the brain.

Bessis A, Champtiaux N, Chatelin L, Changeux JP.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5906-11.

19.

Construction of a novel oncolytic adenoviral vector and its biological characteristics.

Zhang M, Zhang X, Han Z, Chen X, Yang L, Sheng Y, Wen J.

Oncol Rep. 2013 Feb;29(2):798-804. doi: 10.3892/or.2012.2140. Epub 2012 Nov 15.

PMID:
23165979
20.

[HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].

Wang WD, Chen ZT, Li DZ, Duan YZ, Wang ZX, Cao ZH.

Ai Zheng. 2004 Jul;23(7):788-93. Chinese.

PMID:
15248913

Supplemental Content

Support Center